Clinical trial
A Multi-center, Randomized, Double Blind, Dose Escalating Phase III Study on the Efficacy, Safety and Long Term Outcome of Continuous vs. on Demand Treatment of Chronic Spontaneous Urticaria With Rupatadine.
NCT02358265 is registered in ClinicalTrials.gov with Charite University, Berlin, Germany as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Randomized, Double Blind, Dose Escalating Phase III Study on the Efficacy, Safety and Long Term Outcome of Continuous vs. on Demand Treatment of Chronic Spontaneous Urticaria With Rupatadine.
- Lead sponsor
- Charite University, Berlin, Germany
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- December 31, 2014
- Completion date
- June 15, 2018
- Enrollment
- 192 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.